Shingo Kakihara

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6

Shingo Kakihara, Reiji Yoshimura, Koji Shinkai et al. · International Clinical Psychopharmacology · 2005 · 96 citations

Psychotropic Medication, Psychopharmacology, Neuropsychiatry +20

Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients

Reiji Yoshimura, Hikaru Hori, Nobuhisa Ueda et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2007 · 56 citations

Schizophrenic Patients, Psychiatry, Psychotic Disorder +7

Risperidone in the treatment of psychotic depression

Makiko Goto, Reiji Yoshimura, Shingo Kakihara et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2006 · 35 citations

Psychotic Depression, Psychiatry, Psychotic Disorder +8

An open study of risperidone liquid in the acute phase of schizophrenia

Reiji Yoshimura, Jun Nakamura, Koji Shinkai et al. · Human Psychopharmacology Clinical and Experimental · 2005 · 21 citations

Effect of clonazepam treatment on antipsychotic drug‐induced Meige syndrome and changes in plasma levels of GABA, HVA, and MHPG during treatment

Reiji Yoshimura, Shingo Kakihara, Atsushi Soya et al. · Psychiatry and Clinical Neurosciences · 2001 · 11 citations